HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paul, R. Search for Related Content PubMed PubMed Citation Articles by Paul, R.

Comparison of Fluorine-18-2-Fluorodeoxyglucose and Gallium-67 Citrate Imaging for Detection of Lymphoma

Turku Medical Cyclotron Project and Department of Radiotherapy, Turku University Central Hospital, Turku, Finland

Correspondence: For reprints contact: Robert Paul, MD, Dept. of Radiotherapy, Turku University Central Hospital, SF-20520 Turku, Finland.

ABSTRACT

Patients with lymphomas are conventionally imaged with [⁶⁷Ga]citrate for tumor detection and determination of dissemination. Fluorine-18-2-fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) is a radiopharmaceutical that accumulates into tissues where glucose utilization is enhanced, such as tumors. Six cancer patients (five non-Hodgkin's lymphomas, one endodermal retroperitoneal sinus carcinoma) were imaged with [¹⁸F]FDG and [⁶⁷Ga]citrate whole-body scintigraphies in order to compare the sensitivities of these two tumor imaging radiopharmaceuticals. Among the five untreated lymphoma patients, two ⁶⁷Ga scans and four [¹⁸F]FDG scans were positive; in the patient with the retroperitoneal carcinoma who had a positive [¹⁸F]FDG scan before treatment, both scans were negative after treatment. Fluorine-18 FDG may be a more sensitive tumor-detecting radiopharmaceutical for non-Hodgkin's lymphoma than [⁶⁷Ga]citrate.

This article has been cited by other articles:

				T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Maertens, G. Bormans, J. Thomas, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Blood, July 1, 2003; 102(1): 53 - 59. [Abstract] [Full Text] [PDF]

				R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study Radiology, May 1, 2003; 227(2): 353 - 360. [Abstract] [Full Text] [PDF]

				K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Thomas, T. de Groot, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, and G. Verhoef Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann. Onc., September 1, 2002; 13(9): 1356 - 1363. [Abstract] [Full Text] [PDF]

				M. R. Weihrauch, D. Re, K. Scheidhauer, S. Ansen, M. Dietlein, S. Bischoff, H. Bohlen, J. Wolf, H. Schicha, V. Diehl, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease Blood, November 15, 2001; 98(10): 2930 - 2934. [Abstract] [Full Text] [PDF]

				M. Tatsumi, H. Kitayama, H. Sugahara, N. Tokita, H. Nakamura, Y. Kanakura, and T. Nishimura Whole-Body Hybrid PET with 18F-FDG in the Staging of Non-Hodgkin's Lymphoma J. Nucl. Med., April 1, 2001; 42(4): 601 - 608. [Abstract] [Full Text]

				K. Spaepen, S. Stroobants, P. Dupont, S. Van Steenweghen, J. Thomas, P. Vandenberghe, L. Vanuytsel, G. Bormans, J. Balzarini, C. De Wolf-Peeters, et al. Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods? J. Clin. Oncol., January 15, 2001; 19(2): 414 - 419. [Abstract] [Full Text] [PDF]

				V. J Lowe and K. S Naunheim Current role of positron emission tomography in thoracic oncology Thorax, August 1, 1998; 53(8): 703 - 712. [Full Text]

				R. Carr, S. F. Barrington, B. Madan, M. J. O'Doherty, C. A.B. Saunders, J. van der Walt, and A. R. Timothy Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography Blood, May 1, 1998; 91(9): 3340 - 3346. [Abstract] [Full Text] [PDF]